These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 30981686)

  • 1. A global scientific strategy to cure hepatitis B.
    Revill PA; Chisari FV; Block JM; Dandri M; Gehring AJ; Guo H; Hu J; Kramvis A; Lampertico P; Janssen HLA; Levrero M; Li W; Liang TJ; Lim SG; Lu F; Penicaud MC; Tavis JE; Thimme R; ; ; ; Zoulim F
    Lancet Gastroenterol Hepatol; 2019 Jul; 4(7):545-558. PubMed ID: 30981686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global strategies are required to cure and eliminate HBV infection.
    Revill P; Testoni B; Locarnini S; Zoulim F
    Nat Rev Gastroenterol Hepatol; 2016 Apr; 13(4):239-48. PubMed ID: 26907881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meeting the Challenge of Eliminating Chronic Hepatitis B Infection.
    Revill PA; Penicaud C; Brechot C; Zoulim F
    Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 30939846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current status and future directions of hepatitis B antiviral drug discovery.
    Tang L; Zhao Q; Wu S; Cheng J; Chang J; Guo JT
    Expert Opin Drug Discov; 2017 Jan; 12(1):5-15. PubMed ID: 27797587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for Chronic Hepatitis B Virus Infection.
    Bertoletti A; Le Bert N
    Gut Liver; 2018 Sep; 12(5):497-507. PubMed ID: 29316747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activating the innate immune response to counter chronic hepatitis B virus infection.
    Lamb C; Arbuthnot P
    Expert Opin Biol Ther; 2016 Dec; 16(12):1517-1527. PubMed ID: 27603796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
    Lau GK; Cooksley H; Ribeiro RM; Powers KA; Shudo E; Bowden S; Hui CK; Anderson J; Sorbel J; Mondou E; Rousseau F; Lewin S; Perelson AS; Locornini S; Naoumov NV
    Antivir Ther; 2007; 12(5):705-18. PubMed ID: 17713154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: novel therapies for hepatitis B virus cure - advances and perspectives.
    Lin CL; Kao JH
    Aliment Pharmacol Ther; 2016 Aug; 44(3):213-22. PubMed ID: 27302653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune balance in Hepatitis B Infection: Present and Future Therapies.
    Vyas AK; Jindal A; Hissar S; Ramakrishna G; Trehanpati N
    Scand J Immunol; 2017 Jul; 86(1):4-14. PubMed ID: 28387980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).
    Revill P; Locarnini S
    Curr Opin Pharmacol; 2016 Oct; 30():144-150. PubMed ID: 27639371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.
    Moshkani S; Chiale C; Lang SM; Rose JK; Robek MD
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses.
    Ma Z; Zhang E; Yang D; Lu M
    Cell Mol Immunol; 2015 May; 12(3):273-82. PubMed ID: 25418467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-mediated immunotherapy against chronic hepatitis B virus infection.
    Gao Y; Zhang TY; Yuan Q; Xia NS
    Hum Vaccin Immunother; 2017 Aug; 13(8):1768-1773. PubMed ID: 28521640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
    Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
    J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver.
    Dusséaux M; Masse-Ranson G; Darche S; Ahodantin J; Li Y; Fiquet O; Beaumont E; Moreau P; Rivière L; Neuveut C; Soussan P; Roingeard P; Kremsdorf D; Di Santo JP; Strick-Marchand H
    Gastroenterology; 2017 Dec; 153(6):1647-1661.e9. PubMed ID: 28851562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control and Eradication Strategies of Hepatitis B Virus.
    Shih C; Chou SF; Yang CC; Huang JY; Choijilsuren G; Jhou RS
    Trends Microbiol; 2016 Sep; 24(9):739-749. PubMed ID: 27287929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs in the Pipeline for HBV.
    Lopatin U
    Clin Liver Dis; 2019 Aug; 23(3):535-555. PubMed ID: 31266626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular virology of hepatitis B virus and targets for antiviral intervention.
    Glebe D; König A
    Intervirology; 2014; 57(3-4):134-40. PubMed ID: 25034480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA.
    Kumar R; Pérez-Del-Pulgar S; Testoni B; Lebossé F; Zoulim F
    Liver Int; 2016 Jan; 36 Suppl 1():72-7. PubMed ID: 26725901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
    Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.